Belite Bio Inc (BLTE) - News Archive

: Belite Bio, Inc. is advancing its investigational therapeutic, Tinlarebant, targeting Stargardt Disease (STGD1), a hereditary retinal dystrophy causing significant vision loss with no currently approved treatments. Re...

In a significant advancement for the field of ophthalmology, Belite Bio Inc., a pioneering clinical-stage drug development company, has announced the completion of its Phase 3 clinical trial, known as DRAGON, which eval...

Belite Bio s Breakthrough in the Treatment of Stargardt DiseaseBelite Bio Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical company, has recently been thrust into the spotlight with the announcement that the U.S....

Belite Bio Secures $15 Million in Direct Offering Amidst Market FluctuationsSAN DIEGO On February 5, 2025, Belite Bio, Inc. (Nasdaq: BLTE), a clinical-stage biopharmaceutical company specializing in developing therapies...

The development of novel therapeutics for retinal diseases represents a significant frontier in pharmaceutical innovation, especially for conditions like Stargardt Disease (STGD1), which currently lacks effective treatm...

Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical company specializing in novel therapies for degenerative retinal diseases, has achieved a significant milestone. On June 12, 2024, the company announced...

San Diego-based biopharmaceutical firm, Belite Bio, Inc., revealed further key results from its 24-month Phase 2 study of the drug Tinlarebant, which is targeted at treating Stargardt Disease. This announcement took pla...

San Diego-based clinical-stage biopharmaceutical drug development company, Belite Bio, Inc (NASDAQ: BLTE), has taken a significant step forward in its fight against degenerative retinal diseases, announcing on April 25,...

Belite Bio Submits Tinlarebant for Stargardt Disease Clinical Trial in Japan, A Potential Breakthrough for Adolescent PatientsSAN DIEGO, March 22, 2024 - Belite Bio, Inc (NASDAQ: BLTE), a renowned clinical-stage biophar...

Degenerative retinal diseases continue to pose significant challenges in the field of healthcare, requiring innovative therapeutic solutions to address unmet medical needs. In this article, we explore the recent develop...